Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentuximab with Paclitaxel in Advanced Gastric or GEJ Adenocarcinoma
NCT05919381Phase 3Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of gentuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
gentuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05919381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919381.